At the current price of TFC shares, all of the health products under development are a free option with no value given by the market. Yet one over-the-counter (OTC) product is on the market and doing well, and the following are under development:
* Pharma products for six different indications (one post-Stage 2 and three at Stage 2);
* Further OTC products for three more indications (two ready for partner selection and market release within the next 12 months).
The estimated US market size for Acne is >$4B (TFS OTC product already launched), and is >$3.8B for Eczema (TFS product at pre-launch stage). The US market size for Psoriasis is > $5B.
I know from experience that many pharma products can take longer than expected to get to market. But TFS is already well placed for further OTC products for eczema and skin warts to be released over the next year or so. Not bad for a free option.
TFC Price at posting:
$1.52 Sentiment: Buy Disclosure: Held